| Document |
Document Title |
|
WO/2005/100298A1 |
Compounds of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the com...
|
|
WO/2005/100308A1 |
The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted biaryl-methanesulfinyl ace...
|
|
WO2005021515B1 |
The present invention relates to isoxazoline derivatives of structure (I), which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. In particular, compounds disclosed herein can be useful in the treatment of AIDS, as...
|
|
WO/2005/097765A1 |
The present invention relates to compounds of the Formula I, wherein L, X, Y, Z, R1, R2, R3 and R4 are defined herein. The invention also provides methods of using the compounds for inhibition of kinases, more specifically ALK kinases. T...
|
|
WO/2005/097751A2 |
Certain non-imidazole heterocyclic compounds of formula (I) are histamine H3 modulators useful in the treatment of histamine H3 receptor mediated diseases, wherein in the A- and B-containing ring, I) A, B1 and B2 are CH; II) A is CH, one...
|
|
WO/2005/097760A1 |
The present invention relates to substituted prodrug and compositions thereof useful for treating or preventing Hepatitis C virus (HCV) infections. In particular, the present invention relates to prodrugs of substituted diphenyl-, dihete...
|
|
WO/2005/094329A2 |
The present invention provides a compound having Formula (I) or (II): wherein B, R, X, Ar, and Y are defined herein, pharmaceutically acceptable salts thereof and pharmaceutically acceptable prodrugs thereof. The present invention also p...
|
|
WO/2005/095343A1 |
The invention relates to compounds of formula (I), Z-C(R1R2)-C(R3NH2)-C(R4R5)-X-N(R6R7), wherein Z, R1-7 and X have the meaning as cited in the description and the claims. Said compounds are useful as DPP-lV inhibitors. The invention als...
|
|
WO/2005/094810A2 |
The invention provides compounds of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt, for use in the treatment o...
|
|
WO/2005/095361A1 |
The present invention relates to compounds of the Formula I wherein R1, R3, R5, R6, R7, X and Y are as defined. Compounds of the Formula I have activity inhibiting production of Aß-peptide. The invention also relates to pharmaceutical c...
|
|
WO/2005/092316A1 |
The invention provides compounds of formula I or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides ...
|
|
WO/2005/092836A1 |
A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7.including R3', p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for t...
|
|
WO/2005/092011A2 |
The present invention relates to N-substituted benzylic aniline derivatives that are useful for treating cellular proliferative diseases, for treating disorders associated with KSP kinesin activity, and for inhibiting KSP kinesin. The in...
|
|
WO/2005/092869A1 |
A process for producing 1,2-benzisoxazole-3-methanesulfonamide which comprises using 4-hydroxycoumarin as a starting material and water and 1,2-dichloroethane as solvents to produce the target compound without isolating intermediates in ...
|
|
WO/2005/090292A1 |
The invention relates to a compound having general formula (I), wherein: A is selected from among one or more X, Y and/or Z groups; X represents an optionally-substituted methylene group; Y represents a C2-alkenylene, optionally substitu...
|
|
WO/2005/089753A2 |
The present invention concerns the compounds of formula (I) , the substituents being specified in the description, (I) the N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemical Iy isomeric forms thereof , a...
|
|
WO/2005/090322A1 |
The invention relates to a compound having general formula (I), wherein: n = 1 or 2; p represents an integer varying between 1 and 7; A is selected from one or more X, Y and/or Z groups; X = optionally-substituted methylene; Y = C2-alken...
|
|
WO/2005/087710A1 |
A compound represented by the formula (1) (wherein the symbols are the same as defined in the description), a salt thereof, and a prodrug thereof. They unexpectedly have excellent GPR40 receptor agonistic activity and are excellent in pr...
|
|
WO/2005/087215A1 |
The invention relates to acetyl 2-hydroxy-1,3-diaminospirocyclohexanes and derivatives thereof that are useful in treating at least one disease, disorder, and condition associated with amyloidosis. Amyloidosis refers to a collection of d...
|
|
WO/2005/085216A1 |
An isoxazoline-substituted benzamide compound of the general formula: (1) [wherein each of A1, A2 and A3 independently represents a carbon atom or nitrogen atom; G a benzene ring, etc.; W an oxygen atom or sulfur atom; X a halogen atom, ...
|
|
WO/2005/085217A1 |
A process for producing a compound having an anthraquinone skeleton, which is a medical compound, agrichemical compound, dye compound, compound for photographic materials, etc. The compound is a polycyclic compound represented by the fol...
|
|
WO/2005/082871A2 |
The invention relates to guanidine compounds of general formula (I), corresponding enantiomeric, diastereomeric, and/or tautomeric forms thereof, and pharmaceutically acceptable salts thereof. The invention further relates to the use of ...
|
|
WO/2005/080344A1 |
The present invention relates to agricultural insecticide and germicide and discloses substituted azole compounds, its preparation and application. The substituted azole compounds of the present invention is represented as formula (I). T...
|
|
WO/2005/068442A2 |
The present invention refers to isoxazole derivatives, in particular 3,4-diaryl isoxazole derivatives, to their pharmaceutical compositions, the process for preparing them and their use as inhibitors of cycloosygenase, in particular of c...
|
|
WO/2005/068418A1 |
The invention encompasses novel sulfide and disulfide compounds, compositions comprising sulfide and disulfide compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose...
|
|
WO/2005/068420A1 |
The present invention relates to novel urea and thiourea compounds, compositions comprising urea or thiourea compounds, and methods useful for treating and preventing aging, Alzheimer’s Disease, cancer, cardiovascular disease, diabetic...
|
|
WO/2005/068432A1 |
The present invention provides a malononitrile compound represented by the formula (I): wherein any one of X1, X2, X3 and X4 is CR100, wherein R100 is a group represented by the formula: the other three of X1, X2, X3 and X4 each represen...
|
|
WO/2005/068410A1 |
The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders com...
|
|
WO/2005/068412A1 |
The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders c...
|
|
WO/2005/065684A1 |
Compounds having the structure MgX1X2, wherein X1 is parecoxib anion and X2 is as selected from the group consisting of parecoxib anion, chloride, bromide, sulfate, phosphate, nitrate, acetate, propionate, succinate, glycolate, stearate,...
|
|
WO/2005/066164A1 |
A compound of the formula (I); wherein the variables X1 to X10, R1 to R7 including R3', E, W, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, usef...
|
|
WO/2005/066138A1 |
Disclosed are amides of formula (I), wherein the symbols have the meanings indicated in the description, a method for producing said substances, the use thereof for controlling undesired microorganisms, as well as intermediate products o...
|
|
WO/2005/066145A1 |
This invention relates to compounds that are of formula (I) wherein A is heteroaryl and R1 and R2 are both cyclic residues, that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct trea...
|
|
WO/2005/066143A2 |
Methods for increasing D-Serine concentration and reducing concentration of the toxic products of D-Serine oxidation, for enhancing learning, memory and/or cognition, or for treating schizophrenia, Alzheimer's disease, ataxia, or neuropa...
|
|
WO/2005/063705A1 |
Compounds represented by the general formula (1) or (100) have excellent inhibitory activities against cell adhesion and cell infiltration and are useful as therapeutic or preventive agents for various inflammatory and autoimmune disease...
|
|
WO2005040142B1 |
Novel difluorinated amide derivatives of Formula (II) as inhibitors of cathepsin S, K, B, and L, the pharmaceutically acceptable salts and N-oxides thereof, their uses as therapeutic agents and the methods of their making.
|
|
WO/2005/061477A1 |
The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors: Formule (I).
|
|
WO/2005/061459A1 |
The present invention relates to biaryl sulfonamides of the formula 1: wherein: R1 is H or Cl-.C6 a]kyl; R2 is H, C I -C6 alkyl, (CH2)nR2' , phenyl, or benzyl; n is 0-6; R2'is aryl, heteroaryl, cycloalkyl, or heterocycloalkyl; R 3 is, in...
|
|
WO/2005/058884A2 |
The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane c...
|
|
WO/2005/058808A1 |
The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a N-substituted-...
|
|
WO/2005/058845A2 |
Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists. (I) wherein A is (II), (III) or (IV), Y is a valence b...
|
|
WO/2005/057171A2 |
The present invention relates to 1,4-disubstituted naphthalene scaffold compounds and other closely related scaffold compounds. The present invention also relates to combinatorial libraries of such compounds. In addition, the present inv...
|
|
WO/2005/055715A2 |
Certain noel N-(heteroarylalkyl)alkanediamine derivatives have provided unexpected insecticidal and acaricidal activity. These compounds are represented by formula I: wherein Ar, a, r, R, Ra, Rb, Rc, Rd, b, c, Re, Rf, Rg, Rh, R5, d, e, U...
|
|
WO/2005/056540A1 |
This invention relates to compounds of the formula (I) wherein J, M, G, m, X, R', R2, R4, R5, R6, R7, R8, R9, Y, n, z, and R' are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment...
|
|
WO/2005/054174A2 |
The invention relates to compounds for modulating the glycolysis enzyme complex and the transaminase complex, pharmaceutical compositions containing said compounds, and to the uses of said compounds for the production of pharmaceutical c...
|
|
WO/2005/054179A2 |
The invention relates to compounds of general formula I wherein D, E, F, G, W, Y R1, A, R9, X, B, R8 are as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use-alone or in combination with one or...
|
|
WO/2005/054213A1 |
Compounds represented by the formula (I):[wherein R1 to R10 each independently is hydrogen, halogeno, optionally substituted lower alkyl, etc.; X1 is -O-, -S-, -NR11- (wherein R11 is hydrogen, lower alkyl, etc.), -CR12R13CO-, -(CR12R13)m...
|
|
WO/2005/054204A2 |
The invention relates to a class of polycyclic compounds that reacts with and neutralizes a reactive oxygen species, such as a free oxygen radical, in a patient and which can then be regenerated back to their original reactive chemical f...
|
|
WO/2005/051932A1 |
Arylheterocycle derivatives which are represented by the formula (1): (1) wherein R1 represents C1-6 alkyl, etc.; R2 represents halogeno, etc.; m is an integer of 0 to 4; and T represents a group represented by the formula (2), (3), or (...
|
|
WO/2005/051385A1 |
The present invention relates to substituted heterocyclic compounds, such as isoxazoloanthrones, and pharmaceutical compositions thereof that inhibit replication of HCV virus. The present invention also relates to the use of the compound...
|
